A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 19
- Registration Number
- NCT01390337
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Johns Hopkins Medical Institute, Baltimore, Maryland, United States
Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Ara-C, Mitoxantrone, Daunorubicin, Thioguanin
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Prof. Dr. Wolfgang Hiddemann
- Target Recruit Count
- 396
- Registration Number
- NCT01382147
- Locations
- 🇩🇪
Vinzenz-Pallotti-Hospital, Innere Abteilung, Bergisch-Gladbach, Germany
🇩🇪St. Hedwig Krankenhaus, Abteilung Innere Medizin, Berlin, Germany
🇩🇪Vivantes Klinikum Neukoelln, Innere Medizin - Haematologie und Onkologie, Berlin, Germany
Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)Leukemic Dendritic Cell Vaccination
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Mendus
- Target Recruit Count
- 12
- Registration Number
- NCT01373515
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
- First Posted Date
- 2011-05-26
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 20
- Registration Number
- NCT01361334
- Locations
- 🇩🇪
Unviersity Hospital of Münster (UKM), Münster, Germany
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 71
- Registration Number
- NCT01352650
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 90
- Registration Number
- NCT01349049
- Locations
- 🇺🇸
UCSF Helen Diller Family Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Functional Role of RUNX1 Mutations in the Etiology of Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Hillel Yaffe Medical Center
- Target Recruit Count
- 75
- Registration Number
- NCT01329471
- Locations
- 🇮🇱
Hillel Yaffe Medical Center, Hadera, Israel
A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2011-02-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Hetty Carraway
- Target Recruit Count
- 52
- Registration Number
- NCT01305499
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR)
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 120
- Registration Number
- NCT01301820
- Locations
- 🇫🇷
Mathilde HUNAULT BERGER, Angers, France
Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 86
- Registration Number
- NCT01295307
- Locations
- 🇩🇪
HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Klinikum Chemnitz gGmbH, Chemnitz, Germany
🇩🇪University Hospital Carl Gustav Carus, Dresden, Germany